Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Valoctocogene Roxaparvovec
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : BioMarin Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Roctavian (valoctocogene roxaparvovec) is a gene therapy that uses an adeno-associated virus 5, codes for human Factor VIII, together with a human liver-specific promoter. It is currently being investigated for adults with severe hemophilia A.
Product Name : Roctavian
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 07, 2023
Lead Product(s) : Valoctocogene Roxaparvovec
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : BioMarin Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cipaglucosidase Alpha,Miglustat
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Amicus Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Orsini will dispense Pombiliti™ (cipaglucosidase alfa-atga), a hydrolytic lysosomal glycogen-specific enzyme, and Opfolda™ (miglustat), a two-component treatment approved for certain patients with late-onset Pompe disease.
Product Name : Pombiliti
Product Type : Enzyme
Upfront Cash : Undisclosed
September 28, 2023
Lead Product(s) : Cipaglucosidase Alpha,Miglustat
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Amicus Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Pozelimab
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Orsini will be the exclusive specialty pharmacy partner for Veopoz (pozelimab-bbfg), a monoclonal antibody and the first and only treatment for those living with CHAPLE disease.
Product Name : Veopoz
Product Type : Antibody
Upfront Cash : Undisclosed
August 23, 2023
Lead Product(s) : Pozelimab
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fecal Microbiota Spores, Live
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).
Product Name : Vowst
Product Type : Microorganism
Upfront Cash : Inapplicable
June 23, 2023
Lead Product(s) : Fecal Microbiota Spores, Live
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vutrisiran Sodium
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Orsini Specialty Pharmacy Selected as Limited Distribution Partner for Amvuttra™ (vutrisiran)
Details : AMVUTTRA (vutrisiran), is indicated to treat the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The drug works to reduce the production of the transthyretin (TTR) protein in the liver, thereby reducing the levels of TT...
Product Name : Amvuttra
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
July 20, 2022
Lead Product(s) : Vutrisiran Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Avalglucosidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Partnership
Orsini Specialty Pharmacy Selected by Sanofi as a Limited Distribution Partner for Nexviazyme®
Details : Sanofi has selected Orsini Specialty Pharmacy as a distribution partner for Nexviazyme® (avalglucosidase alfa-ngpt), an enzyme replacement therapy (ERT), used for treating patients one year of age and older with late-onset Pompe disease.
Product Name : Nexviazyme
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
September 27, 2021
Lead Product(s) : Avalglucosidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Triheptanoin
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Ultragenyx Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Details : Orsini Pharmaceutical Services has been selected by Ultragenyx Pharmaceutical as a limited distribution specialty pharmacy partner for Dojolvi (triheptanoin). Dojolvi™ is indicated as a source of calories and fatty acids for the treatment of molecularl...
Product Name : Dojolvi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 07, 2020
Lead Product(s) : Triheptanoin
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Ultragenyx Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Lumasiran
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Orsini Specialty Pharmacy been selected by Alnylam® Pharmaceuticals as a limited distribution partner for OXLUMO™. OXLUMO is the first and only treatment approved for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and ...
Product Name : Oxlumo
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 12, 2020
Lead Product(s) : Lumasiran
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership